Remove Drug Pricing Remove Independent Pharmacies Remove Specialty Pharmacies
article thumbnail

Drug Channels News Roundup, February 2021: Accumulator Problems, Humana + ESI, White Bagging Battles, Buy-and-Bill Economics, and Pharmacy Hero Dave Marley

Drug Channels

Let’s melt away this foul February with our monthly selection of scorching news from around the drug channel. In this issue: Payers confess: Patients lose from copay accumulators Humana joins the Express Scripts GPO Hospitals vs. PBMs over specialty pharmacy white bagging Let’s all follow the Buy-and-Bill Dollar!

article thumbnail

NHC Comments on Medicare Drug Price Negotiation Program: Draft Guidance, Implementation of Sections 1191 – 1198 of the Social Security Act for Initial Price Applicability Year 2027 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026 and 2027

Putting Patients First Blog

General Comments The NHC appreciates CMS’ commitment to actively engaging with stakeholders, including patients, consumer advocates, and health experts, in implementing the Medicare Drug Price Negotiation Program (DPNP). Key Medicare tools to safeguard against pharmacy fraud and inappropriate billing do not apply to Part D.

article thumbnail

The Lilly Digest

Ramblings of a pharmacist

Each choice has bearing on the final result that Drug Channels calls out - “IQVIA data show that for 2020, the GDR for unbranded generics in the overall market was 88.5%. The NCPA Digest reports that the GDR for independent pharmacies was only 86% for 2020.” In other words, the $55.96 prescription transaction. .”